Form 8-K - Current report:
SEC Accession No. 0001725160-21-000141
Filing Date
2021-06-08
Accepted
2021-06-08 17:22:57
Documents
12
Period of Report
2021-06-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20210604.htm   iXBRL 8-K 55771
  Complete submission text file 0001725160-21-000141.txt   202578

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20210604.xsd EX-101.SCH 1914
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20210604_lab.xml EX-101.LAB 25998
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20210604_pre.xml EX-101.PRE 13731
5 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20210604_htm.xml XML 11639
Mailing Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 211003085
SIC: 2834 Pharmaceutical Preparations